Navigating 4 Analyst Ratings For Xencor
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings and price targets for Xencor (NASDAQ:XNCR), with 4 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is now $38.00, down from $43.00, with a high estimate of $50.00 and a low of $32.00. Analysts from Mizuho, Guggenheim, RBC Capital, and Wedbush have all lowered their price targets. Xencor is a clinical-stage biopharmaceutical company with positive revenue growth and strong financial health indicators such as ROE and ROA, but with a revenue growth rate lower than the Health Care sector average.
January 22, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have lowered their price targets for Xencor, indicating a bearish sentiment. The average price target has decreased from $43.00 to $38.00, with individual targets ranging from $32.00 to $50.00. Despite this, Xencor shows strong financial health with positive revenue growth and solid ROE and ROA figures.
The lowering of price targets by multiple analysts suggests a bearish outlook for Xencor in the short term, which could lead to a negative impact on the stock price. However, the company's strong financial health metrics may mitigate some of the negative sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100